Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
出版年份 2021 全文链接
标题
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
作者
关键词
-
出版物
Immunotherapy
Volume 13, Issue 8, Pages 637-644
出版商
Future Medicine Ltd
发表日期
2021-04-06
DOI
10.2217/imt-2021-0026
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis
- (2021) Alessandro Rizzo et al. European Urology Focus
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
- (2021) Alessandro Rizzo et al. Future Oncology
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer
- (2020) Robin K. Kelley NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-based therapies for hepatocellular carcinoma
- (2020) David J. Pinato et al. ONCOGENE
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
- (2020) Jörg Trojan DRUGS
- Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
- (2020) Robin Kate Kelley et al. Future Oncology
- Adjuvant systemic treatment in hepatocellular carcinoma: tempted to do something, rather than nothing
- (2020) Alessandro Rizzo et al. Future Oncology
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
- (2020) Robin Park et al. Vaccines
- The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Matthias Pinter et al. JAMA Oncology
- Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
- (2020) Piera Federico et al. Cancers
- Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
- (2020) Mohamed A. Abd El Aziz et al. Vaccines
- Systemic Treatment for Advanced Hepatocellular Carcinoma
- (2019) Mohamed Bouattour et al. Liver Cancer
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Treatment Options in Hepatocellular Carcinoma
- (2019) Lorenza Rimassa et al. Liver Cancer
- Building on the anti-PD1/PD-L1 Backbone: Combination Immunotherapy for Cancer
- (2019) Alvaro H Ingles Garces et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
- (2019) Anne Noonan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cabozantinib for the treatment of hepatocellular carcinoma
- (2019) Nicola Personeni et al. Expert Review of Anticancer Therapy
- The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
- (2019) Ryota Tamura et al. MEDICAL ONCOLOGY
- Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
- (2018) Martin Reck Immunotherapy
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Atezolizumab for the treatment of triple-negative breast cancer
- (2018) Anne-Sophie Heimes et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nivolumab for the treatment of hepatocellular carcinoma
- (2018) Fabian Finkelmeier et al. Expert Review of Anticancer Therapy
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- Novel drugs in clinical development for hepatocellular carcinoma
- (2015) Oliver Waidmann et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started